OCTOBER 8, 2024
Salem Tewolde, Head of Supply Chain, on solving real problems
News & Insights
October 4, 2024
Nomination committee ahead of the annual general meeting 2025
SEPTEMBER 12, 2024
Opioid misuse and overdose in the aging population needs increased attention
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.
Development pipeline targeting large medical needs
ESG sustainable investing
Read all documents related to the refinancing of the existing bond - MARCH 2024
Key financial figures
Group net revenue
615 MSEK
Last Twelve Months, Q323-Q224
Group EBITDA
22 MSEK
Last Twelve Months, Q323-Q224
US Commercial segment EBIT
145 MSEK
Last Twelve Months, Q323-Q224
Cash position
140 MSEK
Q224